logo
Plus   Neg
Share
Email

BGNE Up, Up And Away, Data Vindicates CGEN's Strategy, JNCE Awaits ICONIC Results

Jan18 up 011818 lt

The following are some of today's top gainers in the pharma/biotech sector.

1. Compugen Ltd. (CGEN)

Gained 18.18% to close Thursday's (Jan.18) trading at $3.25.

News: The Company presented new pre-clinical data related to COM701, an immuno-oncology therapeutic antibody candidate.

According to the Company, the data further strengthens its rationale for clinical development plan and biomarker strategy for COM701.

Near-term Catalysts:

-- File IND application for COM701 towards the end of Q1, 2018. COM701 may be tested in the indications of lung, ovary, breast, endometrial, kidney, and head & neck cancers.
-- Initiate phase I study of COM701 in 2018.

Another product candidate is CGEN-15001T mAb, which is being developed in collaboration with Bayer. This compound is currently in IND-enabling studies.

2. Jounce Therapeutics Inc. (JNCE)

Gained 12.80% to close Thursday's trading at $19.47.

News: No news

The Company made its debut on the NASDAQ Global Select Market on January 27, 2017, offering its shares at a price of $16.00 each.

Pipeline:

The Company's lead product candidate is JTX-2011 that is currently in phase II portion of Phase 1/2 trial in patients with solid tumors in both monotherapy and combination settings, dubbed ICONIC.

The Company has a global strategic collaboration with Celgene Corporation (CELG) focused on developing and commercializing innovative immuno-oncology treatments for patients with cancer, including options on JTX-2011.

Near-term Catalyst:

-- Preliminary efficacy evaluation of the ICONIC trial is expected in the first half of 2018.

3. BeiGene Ltd. (BGNE)

Gained 12.60% to close Thursday's trading at $115.56. The stock touched a new high of $119.60 in intraday trading.

News: The Company has priced its follow-on public offering of 7,425,750 American Depositary Shares (ADSs), each representing 13 of its ordinary shares, par value $0.0001 per share, at a price to the public of $101.00 per ADS.

The gross proceeds from the offering are expected to be approximately $750 million, which the Company intends to use for working capital and for research and development activities.

Pipeline:

The Company's pipeline includes BGB-3111 (Zanubrutinib), BGB-A317 (Tislelizumab) and BGB-290 (Pamiparib).

Clinical Trials:

A pivotal phase II trial in China of BGB-3111 in relapsed/refractory mantle cell lymphoma; a global phase III trial of BGB-3111 compared to bendamustine and rituximab in treatment-naïve chronic lymphocytic leukemia / small lymphocytic lymphoma patients; a global pivotal phase II trial of BGB-3111 in combination with GAZYVA in relapsed or refractory follicular lymphoma patients; and a pivotal phase II trial in China of BGB-3111 in Waldenström's macroglobulinemia; a global phase III trial of BGB-3111 compared to bendamustine and rituximab (BR) in treatment-naïve chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) patients and a global pivotal phase II trial of BGB-3111 in combination with GAZYVA in relapsed or refractory follicular lymphoma (FL) patients are underway.

BGB-A317 is under a global phase III clinical trial in patients with previously untreated advanced hepatocellular carcinoma; phase II trial in China in relapsed/refractory classical Hodgkin's lymphoma; a global phase 1a/1b trial in advanced tumors; phase III trial in China as a second- or third-line treatment for patients with advanced lung cancer; pivotal phase II trial in China in previously treated, PD-L1-positive, locally advanced or metastatic urothelial cancer; phase II trial in China in combination with chemotherapy as a first-line treatment for patients with advanced lung cancer; and a phase II trial in China in combination with chemotherapy as a first-line treatment for patients with locally advanced or metastatic esophageal, gastric, or gastroesophageal junction carcinoma.

BGB-290 is under a global phase I trial in combination with temozolomide in locally advanced or metastatic solid tumors, and under a global Phase 1b/2 trial in combination with radiation therapy and/or temozolomide in glioblastoma.

4. GlycoMimetics Inc. (GLYC)

Gained 10.69% to close Thursday's trading at $21.75.

News: No news

Clinical Trials & Near-term Catalysts:

-- Compelling data from phase I/II clinical trial of product candidate GMI-1271 for the treatment of acute myeloid leukemia were presented at the ASH meeting in December. This compound is expected to advance into phase III study in mid-2018.

-- A phase III trial of Rivipansel in patients hospitalized for vaso-occlusive crisis of sickle cell disease is being conducted by the Company's partner Pfizer. This study remains on track for completion in the second half of 2018.

-- Another clinical compound of the Company is GMI-1359, which targets various tumors. A phase I study of GMI-1359 in healthy volunteers is underway.

5. KemPharm Inc. (KMPH)

Gained 10.69% to close Thursday's trading at $5.64.

News: No news

Near-term Catalysts:

-- The FDA decision on resubmitted New Drug Application for Apadaz, an investigational product candidate that is intended to provide short-term management of acute pain, is expected on February 23, 2018.
-- A pivotal efficacy trial of KP415 for the treatment of Attention Deficit, Hyperactivity Disorder is underway, with top line data anticipated in mid-2018, and complete data set expected to be available prior to the end of the year.

6. NuCana plc (NCNA)

Gained 9.69% to close Thursday's trading at $14.49.

News: No news

NuCana went public on the Nasdaq Global Select Market on October 2, 2017, offering its American Depositary Shares at a price of $15 each.

Clinical Trials & Near-term Catalysts:

The Company's lead product candidates are Acelarin and NUC-3373.

Acelarin is currently being evaluated in the indications of ovarian cancer, biliary cancer and pancreatic cancer.

-- On November 15, 2017, the Company announced the enrollment of the first patients in both the United States and the United Kingdom in its phase II study evaluating single-agent Acelarin in patients with platinum-resistant ovarian cancer.
-- A phase III trial comparing Acelarin with gemcitabine for people with pancreatic cancer, dubbed ACELARATE, a phase I study of Acelarin with cisplatin for bile duct cancer, and a phase Ib study of Acelarin and Carboplatin for patients with recurrent ovarian cancer are also underway.

NUC-3373 is currently in a Phase 1 study for the potential treatment of a wide range of advanced solid tumor cancers.

7. Edge Therapeutics Inc. (EDGE)

Gained 8.35% to close Thursday's trading at $11.55.

News: No news

Clinical Trials & Near-term Catalysts:

A phase III study of EG-1962 as a treatment for aneurysmal subarachnoid hemorrhage (aSAH) delivered via external ventricular drain, dubbed NEWTON 2, is ongoing.

-- Top-line efficacy results from the interim analysis of NEWTON 2 study are anticipated in early 2018, and full top line data in the second half of the year.

For comments and feedback contact: editorial@rttnews.com

Business News

RELATED NEWS
Follow RTT